A former executive at Plymouth, Minnesota-based ATS Medical (now part of Medtronic) has taken a position at a California medical device startup.
The company — Santa Rosa-based Direct Flow Medical — announced that David Elizondo is the company’s new chief development officer. Previously, Elizondo was vice president of research & development, and general manager of Tissue Valve Operations at ATS Medical. He has also worked at Boston Scientific and began his career as an engineer at St. Jude Medical.
“Our ability to attract someone of David’s management talent and industry experience is very important to our ongoing success,” said Gordon Bishop, co-founder and chief technology officer, in a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Direct Flow Medical is developing a minimally invasive implant to treat patients with heart valve disease. The product is not limited to aortic valve disease and can be used to treat problems with mitral and other heart valve anatomical sites. In announcing Elizondo’s appointment, the company also highlighted that it got its ninth patent for the Transcatheter Aortic Valve Replacement (TAVR) Technology.
According to regulatory filings, the company raised $40 million in 2009. A statement from the company reveals the company has had three rounds of funding from venture capital firms like New Leaf Venture Partners, Spray Venture Partners, Foundation Medical Partners, VantagePoint Venture Partners and ePlanet Venture Partners.
Founded in 2004, Direct Flow Medical employs 75 people.
